The use of dorzolamide 2% eye drops was found to reduce cystoid macular edema and macular thickness in patients with choroideremia observed by spectral-domain OCT.
Microperimetry has gained increasing clinical interest as a tool for the evaluation of visual function in chorioretinal diseases. 18 This test facilitates allows a real-time functional evaluation, directly correlated to fundus characteristics, with continuous fixation monitoring. In this way, microscotoma of the central visual field are detected under direct visualization, a task not possible with conventional perimetry.
19,20
Although contrast sensitivity is not routinely measured in the clinic, evaluating contrast sensitivity can provide a sensitive index of visual function in patients undergoing treatment with CAIs. 9 Additionally, contrast sensitivity is a good predictor of performance for many everyday activities. 21 The measurement of foveal contrast sensitivity has been recommended as an outcome measure in clinical trials of therapeutic interventions 22 and the usefulness of contrast sensitivity measurement was recently highlighted in an NEI/FDA Ophthalmic Clinical Trial
Design and Endpoints Symposium.
23
The aim of the current study was to determine the efficacy of a topical therapy with dorzolamide 2% ophthalmic solution on the retinal thickness and macular visual function in two choroideremia patients with CME evident on SD-OCT testing. Retinal thickness and macular visual function measurements were performed before the treatment was initiated and at two and five months post-treatment. Measurements of macular visual function included: best-corrected visual acuity, microperimetry sensitivity, Pelli-Robson letter contrast sensitivity (P-R CS), and contrast sensitivity for briefly presented grating targets (grating CS).
Patients and Methods

Patients
Two choroideremia patients with CME evident on SD-OCT testing were informed about the objectives of the study and volunteered to participate. Informed consent was obtained according to the tenets of the Declaration of Helsinki. The study was approved by an institutional review board at the University of Illinois at Chicago.
Clinical Examinations
Ophthalmic examinations included best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement (Goldmann applanation tonometry), and dilated funduscopy using both direct and indirect ophthalmoscopy.
Retinal Thickness Mapping
SD-OCT was performed using a spectral OCT/SLO system (OPKO instrumentations, Miami, FL) to obtain both OCT and SLO images with an axial resolution of <10 microns, and a transverse resolution of 20 microns (in tissue). The system uses an SLO fundus image for alignment, orientation, and registration of the OCT image topographic maps. Both the Line scan (B-scan) and the 3D Retinal Topography scan protocols were used for image acquisition. The
Line scan mode allows the capture of cross-sectional B-scan OCT images of the vitreoretinal, retinal, and chorioretinal structures. We used the "Max Frame Count" of 32 frames. The "Max
Frame Count" is the maximum sequentially captured frames of OCT and SLO images, which are captured and displayed as individual frames. The 3D Retinal Topography mode covers an area of 9.0 x 9.0 mm with a 2.0 mm depth. The retinal thickness map is displayed as 9 ETDRS-like 
Macular Microperimetry (MP) Testing
MP was performed using the OPKO Spectral OCT/SLO system. All tests were performed after dilation of the pupil with 1% tropicamide and 2.5% phenylephrine. The non-tested eye was patched during testing. The subjects underwent a practice test and were instructed to fixate on a red square and to depress a button as soon as they saw the stimulus light. The Polar 3 testing grid was used for all subjects. Polar 3 is a standardized grid composed of 28 points arranged in three concentric circles (2.3°, 6.6°, and 11° in diameter) within the central macula. 
Contrast Sensitivity (CS) Testing
Contrast sensitivity for large letters was measured using the Pelli-Robson contrast sensitivity chart (P-R CS). The test distance was 1 m, as recommended by the manufacturer. P-R CS measurements were obtained from each eye of both patients. Additionally, contrast sensitivity was measured using a 2 cycle-per-degree grating target that was briefly presented (100 ms) on a video display (grating CS). For the grating CS measurement, the patients' task was to judge the grating orientation (horizontal or vertical), and the contrast of the grating was adjusted on each trial to determine contrast sensitivity. For patient 1, grating CS was measured binocularly because fixation was unstable for monocular grating CS measurements. For patient 2, grating CS measurements were only performed in the right eye. For the left eye of this patient, measurements could not be obtained at the maximum contrast that could be produced by the display. Microperimetry testing of 28 individual points within a 6 degree radius from the center of the foveola (12 degree circle, Polar 3 pattern) showed areas of dense scotomas and markedly subnormal individual point sensitivities that were below the 99% confidence limit of normal sensitivity. The overall average test score was 2.3 dB OD and 3.0 dB OS, which was reduced below the lower limit of normal (mean-2SD) at 14.1 dB. 24 The patient showed surprisingly stable foveal fixation in each eye (92% of eye movements were within 2 degrees around the projected fixation target OD and 88% OS).
Results
Patient
At the baseline visit, P-R CS was substantially reduced in both eyes, as compared to normal. 25 The reduction in the left eye (0.65 log units) was greater than that in the right eye (0.50 µm, in the right and left eyes, respectively, (at the 2 months follow-up visit) (Table) .
The overall average test score on MP testing was similar to baseline line in each eye (2.6 dB OD and 3.4 dB OS), which was still reduced below the lower limit of normal at 14.1 dB. The patient showed an improvement in his ocular fixation as 95% of eye movements were within 2 degrees around the projected fixation target OD and 95% OS. (Table) .
No changes in the overall average MP sensitivity values were observed (3.1dB OD and 3.3 dB OS). However, the patient showed a small improvement in his ocular fixation as 100% of eye movements were within 2 degrees around the projected fixation target OD and 100 % OS. Microperimetry testing with the Polar 3 pattern program showed areas of dense scotomas and markedly subnormal individual point sensitivities that were below the 99% confidence limit of normal sensitivity. The overall average test score was 3.0 dB OD and 1.6 dB OS. The patient showed stable foveal fixation in each eye (90% of eye movements within 2 degrees around the projected fixation target OD and 90% OS).
At the baseline visit, P-R CS was substantially reduced in both eyes, as compared to normal. 25 The threshold loss in the left eye (0.80 log units) was greater than that in the right eye (0.65 log units). Measurement of grating CS in the right eye showed a loss of approximately 1.0 log unit, as compared to normal. Grating CS could not be performed in the left eye.
Treatment with topical dorzolamide 2% three times a day in each eye was initiated. After 2 months, the patient reported a moderate subjective improvement of his central vision and also noticed that objects were brighter in the distance. Additionally, the patient noted that his vision was less "hazy." No changes in his peripheral, night, or color vision were subjectively observed. (Table) .
The overall average test score on MP testing was similar to baseline in each eye (3.3 dB OD and 1.5 dB OS), which was still reduced below the lower limit of normal at 14.1 dB. The patient's fixation was stable, with 92% of eye movements were within 2 degrees around the projected fixation target OD and 91% OS. (Table) .
MP testing showed mean sensitivity values with the Polar 3 pattern program of 1.1 dB OS. The patient showed a mild improvement in his ocular fixation as 96% of eye movements were within 2 degrees around the projected fixation target OS. He could not complete the MP testing on his right eye due to eye fatigue.
Following 5 months of treatment, P-R CS remained the same in the right eye, whereas a loss of 0.15 log units was found in the left eye. There was a small loss in grating CS in the right eye (approximately 0.20 log units). The grating CS value following 5 months of treatment (0.68 log units) was very similar to that measured at the baseline visit (0.64 log units). The patient subjectively reported that the "haze" that was present before treatment was initiated had returned. A recent report by Genead and Fishman, 4 showed the presence of variable degrees of CME in 63% of their study cohort of choroideremia patients by SD-OCT examination.
Additionally, this report also documented the presence of thickening of the retina in this group of patients without any statistically significant age-related dependencies that was consistent with 2 previous studies 27, 28 that used time domain-OCT testing on a single choroideremia patient and 21
carriers. The authors 4 speculated that these findings may be attributed to either macular edema or the presence of retinal glial cell proliferation as has been previously described by MacDonald and associates.
29
Our study showed an improvement in central macular thickening due to treatment with topical dorzolamide in macular regions where the SD-OCT scans showed no or only small microcystic changes. The increased macular thickness in these regions may be attributed to accumulation of extracellular and/or intracellular retinal fluid that had not formed cystoid spaces.
Clinical therapeutic trials in a larger group of patients who have macular thickening without marked microcystic macular changes are needed to address this speculation.
Our findings document that the cystoid macular edema seen in patients with choroideremia may favorably respond to treatment with a topical CAI. A precise explanation for Although there were clear improvements in retinal thickness for both patients over the course of treatment, the effects of treatment on visual acuity, microperimetric sensitivity, P-R CS, and grating CS were less or not apparent. For patient 1, visual acuity improved in both eyes by more than 0.2 log MAR over the course of treatment. However, patient 2 had a smaller improvement in acuity in the left eye (approximately 0.1 log MAR) and essentially no improvement in the right eye. Microperimetric sensitivity was substantially reduced for both patients at baseline (more than a 1 log unit loss, as compared to normal) 24 and improvements due to treatment were observed. Similarly, P-R CS was substantially subnormal at baseline for both patients and there was no clinically significant change due to treatment. From the baseline visit to the first follow-up, both patients showed an improvement in grating CS when compared to the baseline visit. However, both patients also showed small losses in grating CS between the first and second follow-up visits. The fluctuation in grating CS in these patients may have been due, at least in part, to fatigue and lapses in attention.
In conclusion, the present study demonstrates that treatment of CME in patients with choroideremia with topical dorzolamide 2% can reduce central macular thickness on SD-OCT
testing with a potential improvement for visual acuity. By comparison, the effect of treatment on microperimetric sensitivity, P-R CS, and grating CS was less apparent in these patients. following two and five months of treatment.
